Pathobiology of primary mediastinal B-cell lymphoma

Stefano A. Pileri, Pier L. Zinzani, Gianluca Gaidano, Brunangelo Falini, Philippe Gaulard, Emenuele Zucca, Elena Sabattini, Stefano Ascani, Maura Rossi, Franco Cavalli

Research output: Contribution to journalArticle

Abstract

Controversy still exists over the response to therapy and prognosis of patients with primary mediastinal B-cell lymphoma (PMBL). Recent data from the International Extranodal Lymphoma Study Group (IELSG) suggest that a MACOP-B (methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone, bleomycin) chemotherapy regimen followed by radiotherapy may be a better induction strategy than other previously used treatments. Although the pathobiology of PMBL has been widely studied, its precise histology, phenotype, and molecular characteristics are still not clear. To date, phenotypic analysis has revealed the following phenotype: positivity for CD45 and CD20, but negativity for CD3, CD10, CD21, Class I/II major histocompatibility antigens, and a variety of other immunohistochemical markers. CD79a is generally detected, despite an absence of surface immunoglobulins (Igs). CD30 staining is observed in most cases, but is weaker and less homogeneous than in classic Hodgkin's lymphoma or anaplastic large cell lymphoma. BCL-2 protein is usually expressed but there are few data describing the expression of MUM1/IRF4, PAX5/BSAP, BCL-6, or the B-cell transcription factors BOB.1, Oct-2, and PU.1. Cytogenetic studies reveal gains in segments of chromosome 9p, including amplification of the REL proto-oncogene and the tyrosine kinase gene JAK2. Other molecular findings include: C-myc mutations or rearrangements, p53 mutations, IgVH gene mutations, and bcl-2 and mal over-expression. bcl-6 mutations and bcl-2 gene rearrangements are generally absent, suggesting that PMBL is of pre-germinal center (GC) origin. However, two recent reports show isotype-switched Ig genes with a high frequency of somatic hypermutations as well as variants in the 5′ noncoding region of the bcl-6 gene. The IELSG collected 137 PMBL cases for extensive pathologic review. Histologically, the lymphomatous growth was predominantly diffuse with sclerosis that induced compartmentalized cell aggregation. It consisted of large cells with varying degrees of nuclear polymorphism and clear to basophilic cytoplasm. Molecular analysis was performed on 40 cases and showed novel findings. More than half of the cases displayed bcl-6 gene mutations, which usually occurred together with functioning somatic IgVH gene mutations, and BCL-6 and/or MUM1/IRF4 expression. The present study supports the concept that PBML is derived from activated GC or post-germinal center cells. However, it differs from other aggressive B-cell lymphomas in that it shows defective Ig production despite the expression of Oct-2, BOB.1, and PU.1 transcription factors, and a lack of IgVH gene crippling mutations.

Original languageEnglish
JournalLeukemia and Lymphoma
Volume44
Issue numberSUPPL. 3
DOIs
Publication statusPublished - 2003

Fingerprint

B-Cell Lymphoma
Mutation
Germinal Center
bcl-2 Genes
Genes
Lymphoma
Transcription Factors
Anaplastic Large-Cell Lymphoma
Phenotype
Cell Aggregation
B-Cell Antigen Receptors
Immunoglobulin Genes
Histocompatibility Antigens Class I
Proto-Oncogenes
Gene Rearrangement
Histocompatibility Antigens Class II
Bleomycin
Sclerosis
Vincristine
Prednisone

Keywords

  • Hematology
  • Induction chemotherapy
  • Pathobiology
  • Primary mediastinal B-cell lyphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Pileri, S. A., Zinzani, P. L., Gaidano, G., Falini, B., Gaulard, P., Zucca, E., ... Cavalli, F. (2003). Pathobiology of primary mediastinal B-cell lymphoma. Leukemia and Lymphoma, 44(SUPPL. 3). https://doi.org/10.1080/10428190310001623810

Pathobiology of primary mediastinal B-cell lymphoma. / Pileri, Stefano A.; Zinzani, Pier L.; Gaidano, Gianluca; Falini, Brunangelo; Gaulard, Philippe; Zucca, Emenuele; Sabattini, Elena; Ascani, Stefano; Rossi, Maura; Cavalli, Franco.

In: Leukemia and Lymphoma, Vol. 44, No. SUPPL. 3, 2003.

Research output: Contribution to journalArticle

Pileri, SA, Zinzani, PL, Gaidano, G, Falini, B, Gaulard, P, Zucca, E, Sabattini, E, Ascani, S, Rossi, M & Cavalli, F 2003, 'Pathobiology of primary mediastinal B-cell lymphoma', Leukemia and Lymphoma, vol. 44, no. SUPPL. 3. https://doi.org/10.1080/10428190310001623810
Pileri SA, Zinzani PL, Gaidano G, Falini B, Gaulard P, Zucca E et al. Pathobiology of primary mediastinal B-cell lymphoma. Leukemia and Lymphoma. 2003;44(SUPPL. 3). https://doi.org/10.1080/10428190310001623810
Pileri, Stefano A. ; Zinzani, Pier L. ; Gaidano, Gianluca ; Falini, Brunangelo ; Gaulard, Philippe ; Zucca, Emenuele ; Sabattini, Elena ; Ascani, Stefano ; Rossi, Maura ; Cavalli, Franco. / Pathobiology of primary mediastinal B-cell lymphoma. In: Leukemia and Lymphoma. 2003 ; Vol. 44, No. SUPPL. 3.
@article{3094d2ad3ef4481aa4f2ab58f7986d5e,
title = "Pathobiology of primary mediastinal B-cell lymphoma",
abstract = "Controversy still exists over the response to therapy and prognosis of patients with primary mediastinal B-cell lymphoma (PMBL). Recent data from the International Extranodal Lymphoma Study Group (IELSG) suggest that a MACOP-B (methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone, bleomycin) chemotherapy regimen followed by radiotherapy may be a better induction strategy than other previously used treatments. Although the pathobiology of PMBL has been widely studied, its precise histology, phenotype, and molecular characteristics are still not clear. To date, phenotypic analysis has revealed the following phenotype: positivity for CD45 and CD20, but negativity for CD3, CD10, CD21, Class I/II major histocompatibility antigens, and a variety of other immunohistochemical markers. CD79a is generally detected, despite an absence of surface immunoglobulins (Igs). CD30 staining is observed in most cases, but is weaker and less homogeneous than in classic Hodgkin's lymphoma or anaplastic large cell lymphoma. BCL-2 protein is usually expressed but there are few data describing the expression of MUM1/IRF4, PAX5/BSAP, BCL-6, or the B-cell transcription factors BOB.1, Oct-2, and PU.1. Cytogenetic studies reveal gains in segments of chromosome 9p, including amplification of the REL proto-oncogene and the tyrosine kinase gene JAK2. Other molecular findings include: C-myc mutations or rearrangements, p53 mutations, IgVH gene mutations, and bcl-2 and mal over-expression. bcl-6 mutations and bcl-2 gene rearrangements are generally absent, suggesting that PMBL is of pre-germinal center (GC) origin. However, two recent reports show isotype-switched Ig genes with a high frequency of somatic hypermutations as well as variants in the 5′ noncoding region of the bcl-6 gene. The IELSG collected 137 PMBL cases for extensive pathologic review. Histologically, the lymphomatous growth was predominantly diffuse with sclerosis that induced compartmentalized cell aggregation. It consisted of large cells with varying degrees of nuclear polymorphism and clear to basophilic cytoplasm. Molecular analysis was performed on 40 cases and showed novel findings. More than half of the cases displayed bcl-6 gene mutations, which usually occurred together with functioning somatic IgVH gene mutations, and BCL-6 and/or MUM1/IRF4 expression. The present study supports the concept that PBML is derived from activated GC or post-germinal center cells. However, it differs from other aggressive B-cell lymphomas in that it shows defective Ig production despite the expression of Oct-2, BOB.1, and PU.1 transcription factors, and a lack of IgVH gene crippling mutations.",
keywords = "Hematology, Induction chemotherapy, Pathobiology, Primary mediastinal B-cell lyphoma",
author = "Pileri, {Stefano A.} and Zinzani, {Pier L.} and Gianluca Gaidano and Brunangelo Falini and Philippe Gaulard and Emenuele Zucca and Elena Sabattini and Stefano Ascani and Maura Rossi and Franco Cavalli",
year = "2003",
doi = "10.1080/10428190310001623810",
language = "English",
volume = "44",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Pathobiology of primary mediastinal B-cell lymphoma

AU - Pileri, Stefano A.

AU - Zinzani, Pier L.

AU - Gaidano, Gianluca

AU - Falini, Brunangelo

AU - Gaulard, Philippe

AU - Zucca, Emenuele

AU - Sabattini, Elena

AU - Ascani, Stefano

AU - Rossi, Maura

AU - Cavalli, Franco

PY - 2003

Y1 - 2003

N2 - Controversy still exists over the response to therapy and prognosis of patients with primary mediastinal B-cell lymphoma (PMBL). Recent data from the International Extranodal Lymphoma Study Group (IELSG) suggest that a MACOP-B (methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone, bleomycin) chemotherapy regimen followed by radiotherapy may be a better induction strategy than other previously used treatments. Although the pathobiology of PMBL has been widely studied, its precise histology, phenotype, and molecular characteristics are still not clear. To date, phenotypic analysis has revealed the following phenotype: positivity for CD45 and CD20, but negativity for CD3, CD10, CD21, Class I/II major histocompatibility antigens, and a variety of other immunohistochemical markers. CD79a is generally detected, despite an absence of surface immunoglobulins (Igs). CD30 staining is observed in most cases, but is weaker and less homogeneous than in classic Hodgkin's lymphoma or anaplastic large cell lymphoma. BCL-2 protein is usually expressed but there are few data describing the expression of MUM1/IRF4, PAX5/BSAP, BCL-6, or the B-cell transcription factors BOB.1, Oct-2, and PU.1. Cytogenetic studies reveal gains in segments of chromosome 9p, including amplification of the REL proto-oncogene and the tyrosine kinase gene JAK2. Other molecular findings include: C-myc mutations or rearrangements, p53 mutations, IgVH gene mutations, and bcl-2 and mal over-expression. bcl-6 mutations and bcl-2 gene rearrangements are generally absent, suggesting that PMBL is of pre-germinal center (GC) origin. However, two recent reports show isotype-switched Ig genes with a high frequency of somatic hypermutations as well as variants in the 5′ noncoding region of the bcl-6 gene. The IELSG collected 137 PMBL cases for extensive pathologic review. Histologically, the lymphomatous growth was predominantly diffuse with sclerosis that induced compartmentalized cell aggregation. It consisted of large cells with varying degrees of nuclear polymorphism and clear to basophilic cytoplasm. Molecular analysis was performed on 40 cases and showed novel findings. More than half of the cases displayed bcl-6 gene mutations, which usually occurred together with functioning somatic IgVH gene mutations, and BCL-6 and/or MUM1/IRF4 expression. The present study supports the concept that PBML is derived from activated GC or post-germinal center cells. However, it differs from other aggressive B-cell lymphomas in that it shows defective Ig production despite the expression of Oct-2, BOB.1, and PU.1 transcription factors, and a lack of IgVH gene crippling mutations.

AB - Controversy still exists over the response to therapy and prognosis of patients with primary mediastinal B-cell lymphoma (PMBL). Recent data from the International Extranodal Lymphoma Study Group (IELSG) suggest that a MACOP-B (methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone, bleomycin) chemotherapy regimen followed by radiotherapy may be a better induction strategy than other previously used treatments. Although the pathobiology of PMBL has been widely studied, its precise histology, phenotype, and molecular characteristics are still not clear. To date, phenotypic analysis has revealed the following phenotype: positivity for CD45 and CD20, but negativity for CD3, CD10, CD21, Class I/II major histocompatibility antigens, and a variety of other immunohistochemical markers. CD79a is generally detected, despite an absence of surface immunoglobulins (Igs). CD30 staining is observed in most cases, but is weaker and less homogeneous than in classic Hodgkin's lymphoma or anaplastic large cell lymphoma. BCL-2 protein is usually expressed but there are few data describing the expression of MUM1/IRF4, PAX5/BSAP, BCL-6, or the B-cell transcription factors BOB.1, Oct-2, and PU.1. Cytogenetic studies reveal gains in segments of chromosome 9p, including amplification of the REL proto-oncogene and the tyrosine kinase gene JAK2. Other molecular findings include: C-myc mutations or rearrangements, p53 mutations, IgVH gene mutations, and bcl-2 and mal over-expression. bcl-6 mutations and bcl-2 gene rearrangements are generally absent, suggesting that PMBL is of pre-germinal center (GC) origin. However, two recent reports show isotype-switched Ig genes with a high frequency of somatic hypermutations as well as variants in the 5′ noncoding region of the bcl-6 gene. The IELSG collected 137 PMBL cases for extensive pathologic review. Histologically, the lymphomatous growth was predominantly diffuse with sclerosis that induced compartmentalized cell aggregation. It consisted of large cells with varying degrees of nuclear polymorphism and clear to basophilic cytoplasm. Molecular analysis was performed on 40 cases and showed novel findings. More than half of the cases displayed bcl-6 gene mutations, which usually occurred together with functioning somatic IgVH gene mutations, and BCL-6 and/or MUM1/IRF4 expression. The present study supports the concept that PBML is derived from activated GC or post-germinal center cells. However, it differs from other aggressive B-cell lymphomas in that it shows defective Ig production despite the expression of Oct-2, BOB.1, and PU.1 transcription factors, and a lack of IgVH gene crippling mutations.

KW - Hematology

KW - Induction chemotherapy

KW - Pathobiology

KW - Primary mediastinal B-cell lyphoma

UR - http://www.scopus.com/inward/record.url?scp=10744221939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744221939&partnerID=8YFLogxK

U2 - 10.1080/10428190310001623810

DO - 10.1080/10428190310001623810

M3 - Article

C2 - 15202521

AN - SCOPUS:10744221939

VL - 44

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - SUPPL. 3

ER -